Milestone Pharmaceuticals Inc.
MIST
$1.34
$0.010.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.75% | 57.97% | 39.55% | 29.43% | 127.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.46% | 52.28% | 23.01% | 29.69% | 95.90% |
| Operating Income | -15.30% | -39.76% | -23.01% | -29.69% | -95.90% |
| Income Before Tax | -25.55% | -40.82% | -26.31% | -38.48% | -100.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.55% | -40.82% | -26.31% | -38.48% | -100.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.55% | -40.82% | -26.31% | -38.48% | -100.51% |
| EBIT | -15.30% | -39.76% | -23.01% | -29.69% | -95.90% |
| EBITDA | -15.18% | -39.77% | -23.07% | -29.75% | -96.17% |
| EPS Basic | 36.11% | 11.96% | 13.32% | -38.02% | -51.74% |
| Normalized Basic EPS | 36.16% | 12.01% | 13.36% | -38.12% | -51.78% |
| EPS Diluted | 36.11% | 11.96% | 13.32% | -38.02% | -51.74% |
| Normalized Diluted EPS | 36.16% | 12.01% | 13.36% | -38.12% | -51.78% |
| Average Basic Shares Outstanding | 96.55% | 60.00% | 45.78% | 0.32% | 32.16% |
| Average Diluted Shares Outstanding | 96.55% | 60.00% | 45.78% | 0.32% | 32.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |